Core Viewpoint - Quantum BioPharma Ltd. announced the publication of a clinical trial demonstrating that its dietary supplement 'unbuzzd' significantly accelerates alcohol metabolism, reduces blood alcohol concentration (BAC), and alleviates symptoms of intoxication and hangover [1][7]. Clinical Trial Findings - The clinical trial was a double-blind, randomized, placebo-controlled study involving healthy participants aged 21 to 43, who consumed alcohol to achieve a BAC between 0.07% and 0.11% before taking either unbuzzd or a placebo [2]. - unbuzzd reduced BAC by more than 40% faster within the first 30 minutes compared to placebo, with continued acceleration observed over a four-hour period [5]. - Participants reported significant improvements in alertness within 30 minutes of consuming unbuzzd, outperforming placebo results [6]. - The supplement stabilized heart rate and blood pressure, which are typically elevated during alcohol intoxication, with these results being statistically significant [6]. - Participants experienced a statistically significant reduction in hangover symptoms, including a 67% reduction in headache severity at four and eight hours post-consumption [6]. Product Information - unbuzzd is a dietary supplement developed by a team of scientists at Quantum BioPharma, comprising a proprietary blend of vitamins and supplements [1][9]. - The product is available for purchase through its website and on Amazon, with various packaging options [10]. - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which markets unbuzzd, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will drop to 3% [12].
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd